MicroPort Scientific Corp., a leading medical device company based in Shanghai (HKG: 0853), has announced the initial clinical applications of its new-generation bioabsorbable stent, Firesorb, across seven clinical centers in five Chinese cities. The product received marketing approval in China in July this year.
Firesorb is a bioabsorbable rapamycin targeted eluting coronary stent system designed for interventional treatment of coronary heart disease. It is capable of fully degrading into water and carbon dioxide within a 3-4 year timeframe, and is absorbed and metabolized by the body. This feature is advantageous for restoring blood vessels to their natural state and enhancing patient comfort. The thrombotic incidence rate in all patients from Phase I, II, and III clinical studies prior to its launch was a mere 0.32%, with a remarkable zero-thrombotic incidence rate at the four-year mark in the RCT study. – Flcube.com
